$XBI $79.84 | -1.63%
Covid Updates
$NVAX -4.4% Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial.
Pipeline Updates
$INCY -0.4% Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer.
$SCYX -25.8% SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections.
$AMPE +13.9% Receipt of written responses from the United States Food and Drug Administration (FDA) pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.
$CVM -9.5% CEL-SCI Announces Acceptance of Abstracts to ASCO 2022.
Business Updates
$ITCI -5.9% Intra-Cellular Therapies initiated at neutral at Piper Sandler on current valuation.
$NKTR +1.3% Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan.
$OTLK -2.9% BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics.
$VLON +100.9% Vallon Pharmaceuticals Announces Review of Strategic Alternatives
$SCYX -25.9% SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants.
$UTHR -1.4% Centers for Medicare and Medicaid Services (CMS) updated its Local Coverage Determination (LCD) for Tyvaso® (treprostinil) Inhalation Solution to include an indication for pulmonary hypertension associated with interstitial lung disease. CMS indicated that this LCD will take effect after a 45-day notice period, becoming effective on June 5, 2022.
Posted by DV/FS
Comments